Literature DB >> 22873529

Use patents, carve-outs, and incentives--a new battle in the drug-patent wars.

Arti Rai1.   

Abstract

Mesh:

Substances:

Year:  2012        PMID: 22873529     DOI: 10.1056/NEJMp1206573

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  1 in total

1.  Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p.

Authors:  James I Barnes; Vasu Divi; Adrian Begaye; Russell Wong; Steven Coutre; Douglas K Owens; Jeremy D Goldhaber-Fiebert
Journal:  Blood Adv       Date:  2018-08-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.